Carnosine / VEGFR2 Cancer Research Results

Carno, Carnosine: Click to Expand ⟱
Features:

Carnosine (CAR; β-alanyl-L-histidine) is an endogenous dipeptide and dietary supplement (high in meat; also synthesized).
Primary mechanisms (conceptual rank):
1) Carbonyl/aldehyde scavenging + anti-glycation (AGE) suppression → proteostasis stress ↓ (P/R)
2) Cancer metabolism interference (Warburg/glycolysis pressure) → proliferation ↓ (model-dependent; often high concentration) (R/G)
3) Metal chelation + ROS/RNS buffering (secondary redox modulation) (P/R; context-dependent)
Bioavailability / PK: Orally absorbed, but rapidly hydrolyzed in human blood by carnosinase (CN1) → very short circulating half-life; sustained systemic CAR exposure is limited vs β-alanine/histidine metabolites.
In-vitro vs realistic exposure: Many anti-proliferative / glycolysis effects are reported at high µM–mM CAR in vitro, commonly exceeding realistic systemic CAR exposure due to rapid serum hydrolysis.
Clinical evidence status (cancer): Predominantly preclinical for direct anti-cancer effects; human oncology evidence is mainly adjunct/supportive (e.g., zinc-L-carnosine for radiation-related symptoms), not established as an anti-tumor monotherapy.

L-Carnosine (usually just called "Carnosine") is a naturally occurring dipeptide composed of L-histidine and β-alanine, found in high concentrations in muscle and brain tissue.
-Source: only found in animals Beef(372mg/100g), ChickenBreast(290mg/100g), Pork(276mg/100g), TurkeyBreast(240mg/100g)
-Anserine is a derivative of carnosine
-Scavenges reactive oxygen species (ROS)
-Inhibits formation of AGEs (advanced glycation end-products), which are linked to aging and neurodegeneration.
-Metal chelator: Binds excess zinc, copper, and iron—important in brain health.


Carnosine (CAR) — Pathway / Axis Effects (Cancer vs Normal)

Rank Pathway / Axis Cancer Cells (↑ / ↓ / ↔) Normal Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 Carbonyl stress / anti-glycation (AGE) ↓ proteotoxic/carbonyl stress (context-dependent) ↓ glycation damage (protective) P/R Cell stress buffering Core “chemoprotective” chemistry: nucleophilic scavenging of reactive carbonyls; cancer-direction depends on whether tumor relies on carbonyl-stress adaptation.
2 Warburg / glycolysis pressure ↓ glycolysis flux (model-dependent; high concentration only) ↔ R/G Anti-proliferative (subset) Frequently reported in vitro with supraphysiologic CAR; translation constrained by rapid serum hydrolysis in humans.
3 Mitochondrial function / energetic stress ↔ / ↑ energetic stress (model-dependent) ↔ / protective (context-dependent) R Growth suppression vs resilience Direction varies by baseline metabolic state and substrate availability; often secondary to carbonyl/redox effects.
4 ROS ↓ ROS (secondary; context-dependent) ↓ oxidative damage (protective) P/R Redox buffering Typically described as antioxidant buffering; paradoxical “ROS ↑” cytotoxicity is not a dominant CAR narrative.
5 NRF2 (stress-response axis) ↔ / ↑ cytoprotection (context-dependent; resistance risk) ↔ / ↑ protective G Adaptive stress signaling If NRF2 is already oncogenic (e.g., KEAP1/NFE2L2-altered tumors), further cytoprotection could be undesirable.
6 Ca²⁺ (ER/mitochondria stress coupling) ↔ (not primary; model-dependent) ↔ R Stress modulation (secondary) Include only as a secondary axis: CAR’s dominant reported levers are carbonyl/redox/metabolic rather than direct Ca²⁺ channel control.
7 Ferroptosis ↔ (context-dependent) ↔ R/G Unclear / secondary CAR’s anti-lipid-peroxidation tendency could oppose ferroptosis in some contexts; evidence is not central vs carbonyl/AGE chemistry.
8 Clinical Translation Constraint Human systemic CAR exposure is constrained by rapid serum hydrolysis (CN1); much in-vitro anti-cancer work uses high µM–mM. Strongest human oncology signal is adjunct/supportive use (e.g., zinc-L-carnosine symptom prevention), not proven tumor regression. — PK-limited; adjunct-only Consider delivery strategies/analogs (e.g., carnosinase-resistant histidine dipeptides) if pursuing systemic pharmacology.

TSF legend: P: 0–30 min (primary/rapid effects; direct enzyme/redox interactions) · R: 30 min–3 hr (acute signaling + stress responses) · G: >3 hr (gene-regulatory adaptation; phenotype outcomes)
VEGFR2, Vascular Endothelial Growth Factor Receptor 2: Click to Expand ⟱
Source:
Type: receptor tyrosine kinase
VEGFR2 is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of new blood vessel formation. In cancer, VEGFR2 is often overexpressed, promoting the growth of new blood vessels that supply the tumor with oxygen and nutrients, facilitating its growth and metastasis.
Inhibiting VEGFR2 signaling has been shown to be an effective strategy in cancer therapy, and several VEGFR2 inhibitors have been approved for the treatment of various types of cancer, including renal cell carcinoma, colorectal cancer, and non-small cell lung cancer. These inhibitors work by blocking the binding of VEGF to VEGFR2, thereby inhibiting angiogenesis and tumor growth.
Scientific Papers found: Click to Expand⟱
3869- Carno,    Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation
- Review, AD, NA - Review, Stroke, NA
*ROS↓, *IronCh↑, *AntiAge↑, *antiOx↑, *Inflam↓, *neuroP↑, *lipid-P↓, *toxicity↓, *NOX4↓, *SOD↑, *HNE↓, *IL6↓, *TNF-α↓, *IL1β↓, *Sepsis↓, *eff↑, *GABA↝, *Aβ↓, Glycolysis↓, AntiTum↑, p‑Akt↓, TumCCA↑, angioG↓, VEGFR2↓, NF-kB↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   HNE↓, 1,   lipid-P↓, 1,   NOX4↓, 1,   ROS↓, 1,   SOD↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

GABA↝, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 19

Scientific Paper Hit Count for: VEGFR2, Vascular Endothelial Growth Factor Receptor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:351  Target#:768  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page